Insight: When the Decision Rests on What We Provide

by: Paul DavidsonPublished on: 25/08/2025

When U.S. Health Secretary Robert F. Kennedy Jr. announced cuts to mRNA vaccine research funding, the reaction wasn’t just political. Scientists worried that the decision rested on incomplete or misleading information. That should sound uncomfortably familiar. In pharma R&D, decision-makers - whether regulators, sponsors, or executives - are equally reliant on the clarity and completeness of what we provide. And too often, omissions creep in: a procedural deviation left unreported, an assay limitation not carried forward, a “minor” inconsistency glossed over. These are rarely malicious. More often, they’re born of pressure - tight budgets, timelines, or assumptions that “everyone knows” the context. Yet the impact can be profound: trials delayed, opportunities lost, or promising therapies abandoned prematurely. Our role in QA is to ensure that the story the data tells is full, clear, and decision-ready. Because the next misinformed decision won’t make headlines - it will happen quietly, in our own organisations.